Denfy’s revamped AML Screening software now includes new risk categories, better PEP status labeling, and other built-in AML ...
M2T-CD33 (LTI-214) has received FDA orphan drug designation, offering incentives like tax credits and market exclusivity for AML treatment. The treatment targets CD33, a glycoprotein present in 90% of ...
Almost a third (32.4%) of inspected firms were not compliant, the report reveals as the SRA prepares to hand over ...
Q3 2025 Management View James Dentzer, President and CEO, emphasized continued progress in the TakeAim Lymphoma study evaluating emavusertib in combination with ibrutinib in primary CNS lymphoma ...
The FDA has approved revumenib (Revuforj; Syndax Pharmaceuticals) for patients 1 year and older with relapsed or refractory acute myeloid leukemia with a susceptible nucleophosmin 1 ( NPM1) mutation ...
The U.S. Food and Drug Administration (FDA) has approved Revuforj (revumenib), which is a menin inhibitor, for the treatment of relapsed or refractory acute myeloid leukemia (AML) with a susceptible ...
The panel reached ≥97.8% consensus on AML management. The panel agreed to use international risk stratification categories for personalized treatment of AML. The presence of ≥10% blasts for recurrent ...
The government has confirmed a landmark reform to the country’s anti-money laundering (AML) and counter-terrorism financing supervision framework, designating the Financial Conduct Authority (FCA) as ...
The Cyprus Securities and Exchange Commission (CySEC) has reached a €150,000 settlement with investment firm Aquilla Nummus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback